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I N T R O D U C T I O N
Transcatheter aortic valve replacement (TAVR) is currently considered a valuable 
alternative for the treatment of severe symptomatic aortic stenosis patients who are 
inoperable or at excessively high surgical risk.1 Although TAVR is associated with high 
success rates and relatively low morbidity and mortality, the incidence of procedural 
complications, namely paravalvular aortic regurgitation, conduction disturbances, vas-
cular complications, stroke, etc. is higher than surgical aortic valve implantation, which 
is still considered the “gold standard” treatment. A large number of new bioprostheses 
is being designed and developed for TAVR in an effort to increase procedural safety 
and make this relatively novel technology available for low surgical risk patients.
T H E  P O R T I C O T M  T I S S U E  V A L V E
The PorticoTM valve (St. Jude Medical Inc, St Paul, MN, USA) is the first fully 
re-sheathable and repositionable (until fully deployed) commercially available tran-
scatheter aortic valve (Figure 1).2,3 The valve is made of bovine leaflets and porcine 
pericardial cuff that are treated with the LinxTM anticalcification treatment, which is 
also used on St. Jude Medical surgical tissue valves (i.e. TrifectaTM).4 Portico is designed 
for leaflet coaptation in round and elliptical annulus configurations. For the moment, 
two sizes are commercially available, 23 mm and 25 mm for aortic annulus dimensions 
19-21 mm and 21-23 mm, respectively. Two additional sizes (27 mm and 29 mm) are 
under clinical evaluation and are expected to become available soon. 
P R E V E N T I O N  O F  P A R A V A L V U L A R  L E A K S
The Portico valve frame has large cells with less metal and more tissue. This 
configuration allows for easier access to the coronary ostia after TAVR and, most 
importantly, it is anticipated to decrease the frequency and the severity of paravalvular 
aortic regurgitation. The potential of a frame strut resting against a calcific nodule 
in the annulus section of the frame is minimized and the tissue can conform better 
around calcific nodules on the native valve leaflets.
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N O  H E M O D Y N A M I C  I N S T A B I L I T Y 
D U R I N G  D E P L O Y M E N T
The valve itself is sutured in the lowest part of the frame 
and is intended to function in an annular position (Figure 2). 
In fact, the valve leaflets function immediately after deploy-
ment of the distal part of the frame. This unique characteristic 
alleviates accuracy during implantation since there is no change 
in the patient’s blood pressure. Also, there is no “parachute 
effect” during deployment and practically no need for rapid 
ventricular pacing.
T H E  P O R T I C O  D E L I V E R Y  S Y S T E M 
–  L O A D I N G  A N D  R E S H E A T H I N G 
F E A T U R E S
The delivery system currently available is designed for 
transfemoral approach via an 18F sheath. A shorter delivery 
system for transaortic/transsubclavian access is under clinical 
evaluation. The valve itself does not need special preparation 
or cold saline immersing before loading on the delivery system. 
Loading takes approximately two minutes, facilitating quick 
valve preparation in case of an emergency. Clockwise rotation 
of the release wheel is used during valve deployment. If need-
ed, the valve can be fully resheathed by counterclockwise rota-
tion of the wheel, provided that the valve is not fully released 
(up to 80-85% is acceptable). The time needed for a complete 
resheath from 80%-deployment position is approximately 15 
seconds. This means that in case of a valve “pop-out”, which 
sometimes occurs with self-expanding devices, the valve can be 
resheathed and redeployed very fast, increasing patients safety. 
Also, this feature makes the Portico system user-friendlier in 
relation to other available TAVR systems. For example, in 
case of a relatively deep deployment of the distal part of the 
stent, there is no need to pull on the system; slight resheathing 
allows for partial valve recapture and deployment can start 
again at the intended depth.
P R E V E N T I O N  O F  H E A R T  B L O C K
The Portico system has some special features to mitigate 
atrioventricular conduction block. The annulus section of the 
valve frame is not flared in order to avoid the trauma on the left 
ventricular outflow track (LVOT), which has been associated 
with heart block. In addition, the optimal depth of implanta-
tion for Portico is 4 mm bellow the aortic annulus, which is 
anticipated to further decrease the occurrence of conduction 
disturbances (Figθρε 2). Finally, the valve frame has almost 
equal radial strength in different degrees of expansion, which 
means that oversizing does not increase a lot compression of 
the LVOT, minimizing potential trauma.
FIGURE 2. The ideal depth of implantation is 4 mm below the 
aortic annulus (range 1-9 mm, highlighted area). The non-flared 
annulus section of the valve and the minimal protrusion of the 
valve in the left ventricular outflow tract are expected to miti-
gate the occurrence of heart block and the need for pacemaker 
implantation.
FIGURE 1. The PorticoTM transcatheter heart valve. The valve 
frame has large cells in order to decrease the incidence of para-
valvular leaks (by accommodating calcific nodules) and to facili-
tate access to the coronary ostia.
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R E L A T E D  S T U D I E S
Initial results in two small non-randomized studies were 
favorable.2,3 The Portico 23 mm valve was implanted in 10 
and 11 patients in Ireland and Canada, respectively.2,3 Valve 
resheathing was used in 6 patients. Patients were followed for 
6-12 months. There was no death, major stroke, new pace-
maker implantation, myocardial infarction, or major vascular 
complication. There were 6 new left bundle branch blocks. 
Echocardiography assessment showed a sustainable increase 
in the valve effective orifice area. No patient had more than 
mild aortic regurgitation at follow-up. 
C O N C L U S I O N S
New generation transcatheter aortic valves are expected 
to expand the indications for TAVR in low surgical risk pa-
tients. The Portico valve has several special features aiming 
to minimize the occurrence of paravalvular aortic regurgita-
tion and heart block, to increase the accuracy of deployment 
and to facilitate better implants. Naturally, favourable initial 
results should be confirmed in large randomized clinical trials. 
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